Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Osteoarthritis and Bone Disorders

Some Placebos More Effective Than Others in Osteoarthritis

Will Boggs, MD  |  July 28, 2015

NEW YORK (Reuters Health)—Some placebos are more effective than others, and these differences can influence the apparent outcomes of clinical trials, according to a systematic review and meta-analysis of osteoarthritis trials. “More surprising than the fact that all placebos are not equal is the magnitude of that difference,” Dr. Raveendhara R. Bannuru, from Tufts Medical…

Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website

Michele B. Kaufman, PharmD, BCGP  |  July 22, 2015

In a 25 month Phase 3 trial, abaloparatide-SC reduced the risk of new fractures in patients suffering from postmenopausal osteoporosis. Plus, the FDA launches a new drug safety website.

Did Reports of Side Effects Contribute to Drop in Bone Drug Use?

Lisa Rapaport  |  July 20, 2015

(Reuters Health)—Media reports raising safety concerns about osteoporosis drugs known as bisphosphonates may have contributed to a sharp drop in their use—even though U.S. doctors and drug regulators haven’t recommended against taking them, a study suggests. Fosamax (alendronate sodium) won U.S. marketing approval in 1995. Widespread use of the drug and others like it over…

Teriparatide to Denosumab Switch Helpful in Osteoporosis

David Douglas  |  July 16, 2015

NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…

Knee Osteoarthritis Pain Worse with Insomnia

Lisa Rapaport  |  June 18, 2015

(Reuters Health)—People suffering from osteoarthritis, the most common type of joint inflammation, are more likely to have knee pain when they also have difficulty getting enough sleep, a study suggests. Researchers found that people with knee osteoarthritis and insomnia were also more likely to suffer from a nervous system disorder called “central sensitization” that makes…

FDA Issues Safety Alerts for Bisphosphonates & SGLT2 Inhibitors

Michele B. Kaufman, PharmD, BCGP  |  May 20, 2015

Safety The Food and Drug Administration (FDA) has updated the Warnings and Precautions sections of prescribing information for the bisphosphonate agents, including risedronate sodium tablets and combinations with calcium (Actonel/Atelvia), alendronate and combinations with vitamin D (Binosto/Fosamax), ibandronate (Boniva), etidronate (Didronel) and the RANK-ligand inhibitor denosumab (Prolia/Xgeva).1 This information relates to an increased risk for…

The pain of knee OA can make exercises challenging.

Physical Therapy, Exercise Advances for Knee Osteoarthritis

Kelli D. Allen, PhD, Yvonne M. Golightly, PT, MS, PhD, and Bryan Heiderscheit, PT, PhD  |  May 15, 2015

Millions of adults suffer from painful knee osteoarthritis (OA). Although physical activity can help improve pain and reduce functional limitations, many people with OA are physically inactive. For people living with knee OA, it can be difficult to get started with or continue on a physical activity program, because pain and other symptoms can make…

2014 ACR/ARHP Annual Meeting: Bone Fracture Concerns in Children

Susan Bernstein  |  April 1, 2015

Recognizing, reducing risk of bone fractures in pediatric patients with rheumatic disease, taking glucocorticoid therapy

2014 ACR/ARHP Annual Meeting: Rheumatologic Research Uncovers Clues to Therapies

Susan Bernstein  |  April 1, 2015

Studies explore role of STING pathway in bone remodeling, denosumab to reduce fracture risk, autotaxin’s role in fibrosis, SSc

Coding Corner Question: April

From the College  |  April 1, 2015

Coding for an office visit by a patient with osteoarthritis who has a dual-energy X-ray absorptiometry (DXA) scan

  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences